AstraZeneca Didn't Deserve Seroquel Extension, DC Circ. Says

Law360, New York (April 26, 2013, 4:25 PM ET) -- The D.C. Circuit on Friday rejected AstraZeneca PLC's bid to overturn the U.S. Food and Drug Administration's approval of generic versions of the antipsychotic drug Seroquel, ruling that the drugmaker wasn't entitled to an extension of exclusivity.

AstraZeneca had claimed it should have gotten three more years of Seroquel exclusivity after it submitted new clinical data in 2008 on possible side effects alongside two supplemental new drug applications for pediatric use of the drug.

Although the FDA approved the sNDAs and gave AstraZeneca three more years...
To view the full article, take a free trial now.
Try Law360 for free for seven days
Already a subscriber? Click here to login

Already have access?

  1. Forgot your password?
  2. Sign In

Get instant access to the one-stop news source for business lawyers

Required